Journal article

Formylpeptide receptor 2: Nomenclature, structure, signalling and translational perspectives: IUPHAR review 35

CX Qin, LV Norling, EA Vecchio, EP Brennan, LT May, D Wootten, C Godson, M Perretti, RH Ritchie

British Journal of Pharmacology | Published : 2022

Abstract

We discuss the fascinating pharmacology of formylpeptide receptor 2 (FPR2; often referred to as FPR2/ALX since it binds lipoxin A4). Initially identified as a low-affinity ‘relative’ of FPR1, FPR2 presents complex and diverse biology. For instance, it is activated by several classes of agonists (from peptides to proteins and lipid mediators) and displays diverse expression patterns on myeloid cells as well as epithelial cells and endothelial cells, to name a few. Over the last decade, the pharmacology of FPR2 has progressed from being considered a weak chemotactic receptor to a master-regulator of the resolution of inflammation, the second phase of the acute inflammatory response. We propose..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Monash University


Funding Acknowledgements

Medical Research Council, Grant/Award Number: MR/N017544/1; National Heart Foundation of Australia, Grant/Award Numbers: 101857, 102787; Versus Arthritis, Grant/Award Number: 22235; Science Foundation Ireland, Grant/Award Number: SFI/15/US B3130; Bristol-Myers Squibb; Barts Charity, Grant/Award Numbers: MGU0443, MGU0489; National Health and Medical Research Council (NHMRC) of Australia, Grant/Award Numbers: ID1120853, ID1145769, ID1155302, ID1187989